Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.

  title={Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.},
  author={Rodney R. Miles and Staci D. Arnold and Mitchell S Cairo},
  journal={British journal of haematology},
  volume={156 6},
Burkitt lymphoma/leukaemia is the most common (40%) form of non-Hodgkin lymphoma that occurs in children and adolescents. The prognosis of advanced (disseminated) Burkitt lymphoma/leukaemia in children and adolescents three decades ago had a 5-year event-free survival (EFS) of <40%, and required combination chemotherapy and radiation therapy over a 1-2 year period. Currently, the prognosis for the same advanced stage has a 5-year EFS of 85-90% with <6 months of chemotherapy only. Radiation… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 22 extracted citations

Flow Cytometry in Pediatric Malignancies.

Indian pediatrics • 2018
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 57 references

Safety, pharmacokinetics (PK) and outcome following Rituximab (R) in combination with FAB chemotherapy in children

M. S. Cairo, J. C. Lynch, +5 authors S. Goldman
View 16 Excerpts
Highly Influenced

Excellent outcome of CNS-positive pediatric Burkitt lymphoma and other mature B-NHL treated with cobmined chemo-immunotherapy (rituximab + FAB

J. K. Frazer, S. C. Goldman, L. Harrison, S. L. Perkins, M. S. Cairo
View 1 Excerpt

Lymphoma. In: Nelson’s Pediatric

I. Waxman, J. Hochberg, M. S. Cairo

Minimal disease assessment in the treatment of children and adolescents

B. Shiramizu, S. Goldman, +9 authors M. S. Cairo

Similar Papers

Loading similar papers…